The majority of heterocycle compounds and typically common heterocycle fragments
present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility …

Prostate cancer (PC) is one of the most common cancers in males and the fifth leading
reason of death. Age, ethnicity, family history, and genetic defects are major factors that …

Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus
mitoxantrone (P<. 001) in postdocetaxel patients with metastatic castration-resistant prostate …

Background In the current treatment of non-small cell lung cancer (NSCLC), traditional
chemotherapy causes high toxicity, so it is necessary to develop safe chemical drug delivery …

Cabazitaxel, a novel tubulin inhibitor with poor affinity for P-glycoprotein, is a second-
generation taxane holding great promise for the treatment of metastatic castration-resistant …

The therapeutic index for chemotherapeutic drugs is determined in part by systemic toxicity,
so strategies for dose intensification to improve efficacy must also address tolerability. In …

Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant
prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium …

Effective anticancer immunity depends on properly activating multiple stepwise events in the
cancer-immunity cycle. An immunologically “cold” tumor microenvironment (TME) …

Taxanes–docetaxel and cabazitaxel–are the most active chemotherapy drugs currently used
for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …